LLY

740.33

+2.22%↑

JNJ

149.28

+0.65%↑

UNH

275.4

+3.05%↑

ABBV

180.67

+2.24%↑

NVO

63.6

-2.53%↓

LLY

740.33

+2.22%↑

JNJ

149.28

+0.65%↑

UNH

275.4

+3.05%↑

ABBV

180.67

+2.24%↑

NVO

63.6

-2.53%↓

LLY

740.33

+2.22%↑

JNJ

149.28

+0.65%↑

UNH

275.4

+3.05%↑

ABBV

180.67

+2.24%↑

NVO

63.6

-2.53%↓

LLY

740.33

+2.22%↑

JNJ

149.28

+0.65%↑

UNH

275.4

+3.05%↑

ABBV

180.67

+2.24%↑

NVO

63.6

-2.53%↓

LLY

740.33

+2.22%↑

JNJ

149.28

+0.65%↑

UNH

275.4

+3.05%↑

ABBV

180.67

+2.24%↑

NVO

63.6

-2.53%↓

Search

Incyte Corp

Abierto

SectorSanidad

63.04 2.57

Resumen

Variación precio

24h

Actual

Mínimo

61.22

Máximo

63.2

Métricas clave

By Trading Economics

Ingresos

-43M

158M

Ventas

-126M

1.1B

P/B

Media del Sector

304.25

56.602

BPA

1.16

Margen de beneficios

15.025

Empleados

2,617

EBITDA

-80M

257M

Recomendaciones

By TipRanks

Recomendaciones

Comprar

Estimación a 12 Meses

+20.77% upside

Dividendos

By Dow Jones

Próximas Ganancias

29 jul 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

-4.3B

12B

Apertura anterior

60.47

Cierre anterior

63.04

Noticias sobre sentimiento de mercado

By Acuity

24%

76%

46 / 382 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Bullish Evidence

Incyte Corp Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

15 may 2025, 22:52 UTC

Ganancias
Principales Movimientos del Mercado

Virgin Galactic Shares Rise on Commercial Spaceflight Plans, Narrower 1Q Loss

15 may 2025, 20:37 UTC

Principales Noticias
Ganancias

Applied Materials Logs Higher 2Q Profit, Revenue as Customer Demand Remains Unchanged

16 may 2025, 00:00 UTC

Charlas de Mercado

Xero Bull Stays Positive on Cost Outlook -- Market Talk

15 may 2025, 23:47 UTC

Charlas de Mercado

Gold Consolidates; Likely Supported by Signs of Disinflation -- Market Talk

15 may 2025, 23:38 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

15 may 2025, 23:38 UTC

Charlas de Mercado

Nikkei May Edge Higher, Tracking Gains Across Most U.S. Equity Markets -- Market Talk

15 may 2025, 23:14 UTC

Principales Noticias

Walmart Becomes Biggest Retailer Yet to Pass Through Tariff Price Increases -- 4th Update

15 may 2025, 22:46 UTC

Principales Noticias
Adquisiciones, fusiones, absorciones

Bayer Seeks New Roundup Settlement While Exploring Monsanto Bankruptcy -- WSJ

15 may 2025, 22:46 UTC

Adquisiciones, fusiones, absorciones

Bayer Working With Restructuring Advisers Latham, AlixPartners to Explore Options for Monsanto -- WSJ

15 may 2025, 22:46 UTC

Adquisiciones, fusiones, absorciones

Bayer Exec Says Company Committed to Resolving Roundup Lawsuits in 18 Months -- WSJ

15 may 2025, 22:46 UTC

Adquisiciones, fusiones, absorciones

Bayer Seeks New Roundup Settlement While Exploring Monsanto Bankruptcy -- WSJ

15 may 2025, 21:58 UTC

Ganancias

Applied Materials Earnings Beat Expectations. Why the Stock Is Down. -- Barrons.com

15 may 2025, 21:24 UTC

Ganancias

Cava's Earnings Beat Expectations. Growth Was Strong Despite Tariff Fears. -- Barrons.com

15 may 2025, 20:56 UTC

Charlas de Mercado

U.S. Spending Downturn Could Lie Ahead -- Market Talk

15 may 2025, 20:54 UTC

Charlas de Mercado
Ganancias

Applied Materials CFO Says Demand Stable Despite Tariffs, Macro -- Market Talk

15 may 2025, 20:54 UTC

Ganancias

Applied Materials Investing to Support Semiconductor Market of More Than $1T by End of Decade, Financial Chief Says

15 may 2025, 20:51 UTC

Ganancias

Applied Materials Financial Chief: Long-Term Secular Growth Drivers Remain Intact

15 may 2025, 20:50 UTC

Charlas de Mercado

Financial Services Roundup: Market Talk

15 may 2025, 20:50 UTC

Adquisiciones, fusiones, absorciones

Berkshire Sells Financial Stocks, Doubles Constellation Stake, Holds Steady on Apple -- WSJ

15 may 2025, 20:50 UTC

Ganancias

Applied Materials' Customer Investments Continue at Expected Rate and Pace, Financial Chief Says

15 may 2025, 20:47 UTC

Ganancias

Applied Materials Not Currently Seeing Large Changes in Customer Demand, CEO Says

15 may 2025, 20:47 UTC

Ganancias

Applied Materials Sees Revenue From Advanced DRAM Customers to Grow 40% in FY25, CEO Says

15 may 2025, 20:47 UTC

Ganancias

Applied Materials Grew Faster Than Peers in Markets Outside China in 2Q, CEO Says

15 may 2025, 20:47 UTC

Ganancias

Applied Materials Underperformed Market in China in 2Q Due to Restrictions on U.S. Companies, CEO Says

15 may 2025, 20:37 UTC

Ganancias

SOS Ltd: Growth Was Fueled by Robust Domestic Demand and Expansion of Pdt Portfolio to Include Rubber and Coal >SOS

15 may 2025, 20:37 UTC

Ganancias

SOS Ltd: Cryptocurrency Mining Rev Declined to $9.3M From $18.9M in FY23, Dip Was Attributed to the Temporary Shutdown of Texas Mining Facility for Upgrades During 1H 2024 >SOS

15 may 2025, 20:37 UTC

Ganancias

SOS Ltd: FY24 Significant Yr-over-Yr Increase in Commodity Trading Rev, Which Soared to $214.3M FY24, 92.6% of Total Rev Up From 74.0% in FY23 >SOS

15 may 2025, 20:37 UTC

Ganancias

SOS Ltd: Cryptocurrency Mining Rev Halves as SOS Focuses on Facility Upgrades and Commodity Expansion >SOS

15 may 2025, 20:26 UTC

Principales Noticias

Trump Presses Apple to Bring iPhone Manufacturing to America. Wall Street Shrugs. -- WSJ

15 may 2025, 20:25 UTC

Ganancias

Deere Stock Jumps on Guidance Cut. Here's Why. -- Barrons.com

Comparación entre iguales

Cambio de precio

Incyte Corp previsión

Precio Objetivo

By TipRanks

20.77% repunte

Estimación a 12 Meses

Media 73.86 USD  20.77%

Máximo 95 USD

Mínimo 52 USD

De acuerdo con 18 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Incyte Corp Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

18 ratings

6

Comprar

11

Mantener

1

Vender

Puntuación técnica

By Trading Central

59.52 / 62.66Soporte y Resistencia

Corto Plazo

Bullish Evidence

Medio plazo

Bearish Evidence

Largo Plazo

Bearish Evidence

Sentimiento

By Acuity

46 / 382 Clasificación en Sanidad

Noticias sobre sentimiento de mercado

Coyuntura alcista notoria

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Incyte Corp

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis. Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors. The company also develops INCB123667, INCA32459, and INCA33890, as well as Ruxolitinib cream, Povorcitinib, and INCA034460. It has collaboration out-license agreements with Novartis and Lilly; in-license agreements with Agenus, Merus, MacroGenics, and Syndax; and collaboration and license agreement with China Medical System Holdings Limited for the development and commercialization of povorcitinib. The company sells its products to specialty, retail, and hospital pharmacies, distributors, and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation